Progestins prescribed to a large number of women lead to an increased risk of brain tumors, confirm French researchers.
“This is a global public health problem!” warn about Parisian Alain Weil, deputy director of the Epi-Phare group, the health insurance alliance and the National Agency for the Safety of Medicines (ANSM). According to a study conducted by this researcher and his team, “Long-term use of progestone (Surgestone 0.5 mg), medrogestone (Colprona 5 mg), or medroxyprogesterone acetate (Depo-Provera 150 mg/3 ml) is associated with an increased risk of meningioma.”. The results – on the risks of brain tumors associated with these progestins – were published in French last July but were published Wednesday evening in the journal. British[…]
The rest is reserved for subscribers.
Login to read content
Or